Join Dr. Agne Straukiene, a neurologist specialising in Multiple Sclerosis, as she unveils groundbreaking treatments discussed at the ECTRIMS 2025 conference. Discover how BTK inhibitors like #Tolebrutinib, #Evobrutinib, #Orelabrutinib, #Remibrutinib, and #Fenebrutinib could revolutionize MS care by targeting both B cells and brain cells to reduce inflammation and progression. Learn about #Frexalimab's novel mechanism and promising trial results, the potential of combining #Clemastine and #Metformin for myelin repair, and remarkable long-term outcomes of autologous haematopoietic stem cell transplantation. Explore the exciting advent of #CART cell therapy poised to change the future of MS treatment.00:00 Introduction to MS and ECTRIMS 202500:24 Understanding BTK Inhibitors01:05 Key BTK Inhibitors Discussed04:00 Frexalimab: A New Approach05:09 Combination Therapies: Clemastine and Metformin06:05 Stem Cell Therapy: Long-term Outcomes07:43 CAR T Cell Therapy: Cutting-edge Treatment08:57 Conclusion and Future OutlookBecome a supporter of this podcast: https://www.spreaker.com/podcast/beewellwithms-podcast-by-dr-agne-straukiene--5762905/support.This episode includes AI-generated content.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related